Abstract
Background The NIA-AA proposed Amyloid-Tau-Neurodegeneration (ATN) as a classification system for AD biomarkers. The Amyloid Cascade Hypothesis (ACH) implies a sequence across ATN groups that patients might undergo during transition from healthy towards AD: A-T-N-→A+T-N-→A+T+N-→A+T+N+. Here we assess the evidence for monotonic brain volume decline for this particular (Amyloid-conversion first, Tau-conversion second, N-conversion last) and alternative progressions using Voxel-based Morphometry (VBM) in a large cross-sectional MRI cohort.
Methods We used baseline data of the DELCODE cohort of 437 subjects (127 Controls, 168 SCD, 87 MCI, 55 AD patients) which underwent lumbar puncture, MRI scanning and neuropsychological assessment. ATN classification was performed using CSF-Aβ42/Aβ40 (A+/-), CSF-phospho-Tau (T+/-), and adjusted hippocampal volume or CSF-total-Tau (N+/-). We compared voxel-wise model evidence for monotonic decline of gray matter volume across various sequences over ATN groups using the Bayesian Information Criterion (including also ROIs of Braak stages). First, face validity of the ACH transition sequence A-T-N-→A+T-N-→A+T+N-→A+T+N+ was compared against biologically less plausible (permuted) sequences among AD-continuum ATN groups. Second, we evaluated evidence for 6 monotonic brain volume progressions from A-T-N-towards A+T+N+ including also non-AD-continuum ATN groups.
Results The ACH-based progression A-T-N-→A+T-N-→A+T+N-→A+T+N+ was consistent with cognitive decline and clinical diagnosis. Using hippocampal volume for operationalization of neurodegeneration (N), ACH was most evident in 9% of gray matter predominantly in the medial temporal lobe. Many cortical regions suggested alternative non-monotonic volume progressions over ACH progression groups, which is compatible with an early amyloid-related tissue expansion or sampling effects e.g. due to brain-reserve. Volume decline in 65% of gray matter was consistent with a progression where A status converts before T or N status (i.e. ACH/ANT) when compared to alternative sequences (TAN/TNA/NAT/NTA). Brain regions earlier affected by Tau tangle deposition (Braak stage I-IV, MTL, limbic system) present stronger evidence for volume decline than late Braak-stage ROIs (V/VI, cortical regions). Similar findings were observed when using CSF-total-Tau for N instead.
Conclusion Using the ATN classification system, early Amyloid status conversion (before Tau and Neurodegeneration) is associated with brain volume loss observed during AD progression. The ATN system and the ACH are compatible with monotonic progression of MTL atrophy.
DRKS00007966, 04/05/2015, retrospectively registered
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by the German Center for Neurodegenerative Diseases (Deutsches Zentrum fuer Neurodegenerative Erkrankungen (DZNE)), reference number BN012.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the ethical committees of the medical faculties of all participating sites: the ethical committees of Berlin (Charite, University Medicine), Bonn, Cologne, Goettingen, Magdeburg, Munich (Ludwig-Maximilians-University), Rostock, and Tuebingen. The process was led and coordinated by the ethical committee of the medical faculty of the University of Bonn. All commitees gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Shared last-authorship,
Data Availability
The code used during the current study are available from the corresponding author on reasonable request. Data, study protocol and biomaterials can be shared with partners based on individual data- and biomaterial transfer agreements. Requests can be addressed to the DELCODE steering committee
Glossary
- ACH
- Amyloid Cascade Hypothesis
- AD
- Alzheimer’s disease
- DAT
- Dementia of Alzheimer’s type
- aHV
- Adjusted hippocampal volume
- AN(C)OVA
- Analysis of (co-) variance
- ATN
- Classification based on Amyloid / Tau / Neurodegeneration pathology
- BIC
- Bayesian Information Criterion
- CAT
- Computational Anatomy Toolbox
- CDR
- Clinical Dementia Rating
- CERAD
- Consortium to establish a registry for Alzheimer’s disease
- NC
- Non-complaining healthy control
- CSF
- Cerebrospinal fluid
- FDR
- False Discovery Rate
- FLAIR
- Fluid attenuated inversion recovery
- GM
- Gray matter
- MCI
- Mild Cognitive Impairment
- MMSE
- Mini-mental state examination
- MPRAGE
- Magnetization prepared rapid gradient echo
- MRI
- Magnetic resonance imaging
- MTL
- Medial temporal lobe
- NFT
- Neurofibrillary tangles
- ROI
- Region of interest
- SCD
- Subjective Cognitive Decline
- SPM
- Statistical Parametric Mapping
- TICV
- Total intracranial volume
- VBM
- Voxel-based Morphometry
- WM
- White matter
- WMH
- White matter hyperintensities